The extent of cyclin D1 expression in endometrial pathologies and relevance of cyclin D1 with the clinicopathological features of endometrioid endometrial carcinoma

Yıldırım, Hülya Tosun; Nergiz, Döndü; Sadullahoğlu, Canan; Akgunduz, Zelal; Yıldırım, Şenay; Doğan, Selen; Sezer, Cem

doi:10.4103/ijpm.ijpm_589_19

Cited by 6 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings indicate that abnormal Wnt/β-catenin pathway activation could lead to enhanced migration and invasion of menstrual endometrial cells in endometriosis patients [57]. Cyclin D1 expression was shown to be higher in the secretory phase stromal cells of patients with endometriosis than in the secretory phase stromal cells of healthy women [58]. In this study, a significant increase in β-catenin and Cyclin D1 was observed in E-MenSCs compared to NE-MenSCs, which is quite consistent with the observations of previous studies [20,59,60].…”

Section: Enhanced Migratory and Angiogenicmentioning

confidence: 77%

A Comparative Study of Gene Expression in Menstrual Blood-Derived Stromal Cells between Endometriosis and Healthy Women

Sahraei

Asl

Kalhor

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. Research into the pathogenesis of endometriosis would substantially promote its effective treatment and early diagnosis. Currently, accumulating evidence has shed light on the importance of endometrial stem cells within the menstrual blood which are involved in the establishment and progression of endometriotic lesions in a retrograde manner. Objectives. We aimed to identify the differences in some genes’ expression between menstrual blood-derived mesenchymal stem cells (MenSCs) isolated from endometriosis patients (E-MenSCs) and MenSCs from healthy women (NE-MenSCs). Methods. Menstrual blood samples (2-3 mL) from healthy and endometriosis women in the age range of 22–35 years were collected. Isolated MenSCs by the Ficoll-Paque density-gradient centrifugation method were characterized by flow cytometry. MenSCs were evaluated for key related endometriosis genes by real-time-PCR. Results. E-MenSCs were morphologically different from NE-MenSCs and showed, respectively, higher and lower expression of CD10 and CD9. Furthermore, E-MenSCs had higher expression of Cyclin D1 (a cell cycle-related gene) and MMP-2 and MMP-9 (migration- and invasion-related genes) genes compared with NE-MenSCs. Despite higher cell proliferation in E-MenSCs, the BAX/BCL-2 ratio was significantly lower in E-MenSCs compared to NE-MenSCs. Also, the level of inflammatory genes such as IL1β, IL6, IL8, and NF-κB and stemness genes including SOX2 and SALL4 was increased in E-MenSCs compared with NE-MenSCs. Further, VEGF, as a potent angiogenic factor, showed a significant increase in E-MenSCs rather than NE-MenSCs. However, NE-MenSCs showed increased ER-α and β-catenin when compared with E-MenSCs. Conclusion. Here, we showed that there are gene expression differences between E-MenSCs and NE-MenSCs. These findings propose that MenSCs could play key role in the pathogenesis of endometriosis and further support the menstrual blood retrograde theory of endometriosis formation. This could be of great importance in exploiting promising therapeutic targets and new biomarkers for endometriosis treatment and prognosis.

show abstract

Section: Enhanced Migratory and Angiogenicmentioning

confidence: 77%

A Comparative Study of Gene Expression in Menstrual Blood-Derived Stromal Cells between Endometriosis and Healthy Women

Sahraei

Asl

Kalhor

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…As an oncogene, dysregulation of CCND1 compromises the S-phase checkpoint, inducing forced progression of the cell cycle, disrupting DNA replication, and promoting DNA damage and genomic instability, resulting in oncogenesis [45]. CCND1 is more frequently deregulated than CCND2 and CCND3 in both solid and haematological cancers [46], and is over-expressed and upregulated in multiple cancers, including head and neck squamous carcinoma [47], mantle cell lymphoma [48], pancreatic cancer [49], melanoma [50], non-small cell lung cancer [51], gastric cancer [52], colorectal cancer [53], endometrial cancer [54], and over 50% of human breast cancers [55]. The oncogenic activity of CCND1 is strongly tied to its cellular levels, as tumour cells with high CCND1 levels exhibit uncontrolled cell proliferation.…”

Section: Cyclin D1mentioning

confidence: 99%

D-Type Cyclins in Development and Disease

Saleban,

Harris,

Poulter

2023

Genes

View full text Add to dashboard Cite

D-type cyclins encode G1/S cell cycle checkpoint proteins, which play a crucial role in defining cell cycle exit and progression. Precise control of cell cycle exit is vital during embryonic development, with defects in the pathways regulating intracellular D-type cyclins resulting in abnormal initiation of stem cell differentiation in a variety of different organ systems. Furthermore, stabilisation of D-type cyclins is observed in a wide range of disorders characterized by cellular over-proliferation, including cancers and overgrowth disorders. In this review, we will summarize and compare the roles played by each D-type cyclin during development and provide examples of how their intracellular dysregulation can be an underlying cause of disease.

show abstract

“…Cyclin D1 upregulation has been seen in at least 11 kinds of cancers, including head and neck squamous cell carcinoma ( 12 ), non-small-cell lung cancer (NSCLC) ( 13 ), endometrial cancer ( 14 ), melanoma ( 15 ), pancreatic cancer ( 16 , 17 ), gastric cancer ( 18 ), breast cancer ( 19 ), colorectal cancer ( 20 ), mantle cell lymphoma ( 21 ), multiple myeloma ( 22 ), and prostate cancer ( 23 ). The prevailing view is that high levels of cyclin D1 expression have a positive correlation with poor prognosis in a wide variety of tumors such as nasopharyngeal carcinoma (NPC) ( 24 ), gastric cancer tissues ( 25 ), and squamous cell carcinoma of the head and neck ( 12 , 26 ).…”

Section: Introductionmentioning

confidence: 99%

Degradation strategy of cyclin D1 in cancer cells and the potential clinical application

Chen

2022

Front. Oncol.

View full text Add to dashboard Cite

Cyclin D1 has been reported to be upregulated in several solid and hematologic tumors, promoting cancer progression. Thus, decreasing cyclin D1 by degradation could be a promising target strategy for cancer therapy. This mini review summarizes the roles of cyclin D1 in tumorigenesis and progression and its degradation strategies. Besides, we proposed an exploration of the degradation of cyclin D1 by FBX4, an F box protein belonging to the E3 ligase SKP-CUL-F-box (SCF) complex, which mediates substrate ubiquitination, as well as a postulate about the concrete combination mode of FBX4 and cyclin D1. Furthermore, we proposed a possible photodynamic therapy strategythat is based on the above concrete combination mode for treating superficial cancer.

show abstract

The extent of cyclin D1 expression in endometrial pathologies and relevance of cyclin D1 with the clinicopathological features of endometrioid endometrial carcinoma

Cited by 6 publications

References 23 publications

A Comparative Study of Gene Expression in Menstrual Blood-Derived Stromal Cells between Endometriosis and Healthy Women

A Comparative Study of Gene Expression in Menstrual Blood-Derived Stromal Cells between Endometriosis and Healthy Women

D-Type Cyclins in Development and Disease

Degradation strategy of cyclin D1 in cancer cells and the potential clinical application

Contact Info

Product

Resources

About